{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T14:05:08Z","timestamp":1774188308243,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,30]]},"DOI":"10.7759\/cureus.23647","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T15:15:45Z","timestamp":1648653345000},"source":"Crossref","is-referenced-by-count":4,"title":["The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Carolina","family":"Sepulveda Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Thornburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Lacatusu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reece","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pacciulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulma","family":"Moredo Loo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Yee","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthikeyan","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin J","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum MF","year":"2018","unstructured":"Grunebaum MF, Galfalvy HC, Choo TH, et al.. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018, 175:327-35. 10.1176\/appi.ajp.2017.17060647","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2017.0684","article-title":"Taking psychedelics seriously","volume":"21","author":"Byock I","year":"2018","unstructured":"Byock I. Taking psychedelics seriously. J Palliat Med. 2018, 21:417-21. 10.1089\/jpm.2017.0684","journal-title":"J Palliat Med"},{"key":"ref3","article-title":"Ketamine Toxicity","author":"Orhurhu VJ","year":"2022","unstructured":"Orhurhu VJ, Vashisht R, Claus LE, Cohen SP. Ketamine Toxicity. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6932a1","article-title":"Mental health, substance use, and suicidal ideation during the COVID-19 pandemic - United States, June 24-30","volume":"69","author":"Czeisler M\u00c9","year":"2020","unstructured":"Czeisler M\u00c9, Lane RI, Petrosky E, et al.. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic - United States, June 24-30. MMWR Morb Mortal Wkly Rep. 2020, 69:1049-57. 10.15585\/mmwr.mm6932a1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref5","article-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed.","author":"American Psychiatric Association","year":"2017","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed.. American Psychiatric Association, Washington, DC; 2017."},{"key":"ref6","unstructured":"NAMCS. national summary tables. (2018). Accessed: February 2, 2022: https:\/\/www.census.gov\/programs-surveys\/namcs.html."},{"key":"ref7","unstructured":"CDC. National health interview survey. (2019). Accessed: February 2, 2022: https:\/\/www.cdc.gov\/nchs\/nhis\/2019nhis.htm."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-4950-4","article-title":"Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression","volume":"235","author":"Levy MJ","year":"2018","unstructured":"Levy MJ, Boulle F, Steinbusch HW, van den Hove DL, Kenis G, Lanfumey L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology (Berl). 2018, 235:2195-220. 10.1007\/s00213-018-4950-4","journal-title":"Psychopharmacology (Berl)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes BN","year":"2020","unstructured":"Gaynes BN, Lux L, Gartlehner G, et al.. Defining treatment-resistant depression. Depress Anxiety. 2020, 37:134-45. 10.1002\/da.22968","journal-title":"Depress Anxiety"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava M","year":"2021","unstructured":"Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, Sheehan JJ. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021, 82:20m13699. 10.4088\/JCP.20m13699","journal-title":"J Clin Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.22365\/jpsych.2018.294.291","article-title":"Electroconvulsive therapy: 80 years of use in psychiatry (Article in Modern Greek)","volume":"29","author":"Kaliora SC","year":"2018","unstructured":"Kaliora SC, Zervas IM, Papadimitriou GN. Electroconvulsive therapy: 80 years of use in psychiatry (Article in Modern Greek). Psychiatriki. 2018, 29:291-302. 10.22365\/jpsych.2018.294.291","journal-title":"Psychiatriki"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/ANA.0000000000000511","article-title":"Ketamine anesthesia does not improve depression scores in electroconvulsive therapy: a randomized clinical trial","volume":"30","author":"Carspecken CW","year":"2018","unstructured":"Carspecken CW, Borisovskaya A, Lan ST, Heller K, Buchholz J, Ruskin D, Rozet I. Ketamine anesthesia does not improve depression scores in electroconvulsive therapy: a randomized clinical trial. J Neurosurg Anesthesiol. 2018, 30:305-13. 10.1097\/ANA.0000000000000511","journal-title":"J Neurosurg Anesthesiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0000000000000607","article-title":"Ketamine and electroconvulsive therapy: so happy together?","volume":"31","author":"Cobb K","year":"2018","unstructured":"Cobb K, Nanda M. Ketamine and electroconvulsive therapy: so happy together?. Curr Opin Anaesthesiol. 2018, 31:459-62. 10.1097\/ACO.0000000000000607","journal-title":"Curr Opin Anaesthesiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S221437","article-title":"Ketamine and depression: a narrative review","volume":"13","author":"Corriger A","year":"2019","unstructured":"Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019, 13:3051-67. 10.2147\/DDDT.S221437","journal-title":"Drug Des Devel Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2019.1640604","article-title":"Esketamine for treatment resistant depression","volume":"19","author":"Swainson J","year":"2019","unstructured":"Swainson J, Thomas RK, Archer S, et al.. Esketamine for treatment resistant depression. Expert Rev Neurother. 2019, 19:899-911. 10.1080\/14737175.2019.1640604","journal-title":"Expert Rev Neurother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly EJ","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, et al.. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018, 75:139-48. 10.1001\/jamapsychiatry.2017.3739","journal-title":"JAMA Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova V","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, et al.. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019, 176:428-38. 10.1176\/appi.ajp.2019.19020172","journal-title":"Am J Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso CM","year":"2018","unstructured":"Canuso CM, Singh JB, Fedgchin M, et al.. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018, 175:620-30. 10.1176\/appi.ajp.2018.17060720","journal-title":"Am J Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu DJ","year":"2020","unstructured":"Fu DJ, Ionescu DF, Li X, et al.. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020, 81:19-13191. 10.4088\/JCP.19m13191","journal-title":"J Clin Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120959644","article-title":"Ketamine: a tale of two enantiomers","volume":"35","author":"Jelen LA","year":"2021","unstructured":"Jelen LA, Young AH, Stone JM. Ketamine: a tale of two enantiomers. J Psychopharmacol. 2021, 35:109-23. 10.1177\/0269881120959644","journal-title":"J Psychopharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji A","year":"2021","unstructured":"Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021, 278:542-55. 10.1016\/j.jad.2020.09.071","journal-title":"J Affect Disord"},{"key":"ref22","unstructured":"Suicidal ideation. (2021). Accessed. February 2, 2022: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK565877\/."},{"key":"ref23","unstructured":"Provisional numbers and rates of suicide by month and demographic characteristics. United States, 2020. (2021). Accessed: February 2, 2022: https:\/\/stacks.cdc.gov\/view\/cdc\/110369."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson ST","year":"2018","unstructured":"Wilkinson ST, Ballard ED, Bloch MH, et al.. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018, 175:150-8. 10.1176\/appi.ajp.2017.17040472","journal-title":"Am J Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S157233","article-title":"A review of ketamine's role in ECT and non-ECT settings","volume":"14","author":"Jankauskas V","year":"2018","unstructured":"Jankauskas V, Necyk C, Chue J, Chue P. A review of ketamine's role in ECT and non-ECT settings. Neuropsychiatr Dis Treat. 2018, 14:1437-50. 10.2147\/NDT.S157233","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2018.12.009","article-title":"Electroconvulsive therapy (ECT) vs. ketamine in patients with treatment-resistant depression: the ELEKT-D study protocol","volume":"77","author":"Mathew SJ","year":"2019","unstructured":"Mathew SJ, Wilkinson ST, Altinay M, et al.. Electroconvulsive therapy (ECT) vs. ketamine in patients with treatment-resistant depression: the ELEKT-D study protocol. Contemp Clin Trials. 2019, 77:19-26. 10.1016\/j.cct.2018.12.009","journal-title":"Contemp Clin Trials"},{"key":"ref27","unstructured":"Help with addiction and substance use disorders . (2022). Accessed. February 2, 2022: https:\/\/www.psychiatry.org\/patients-families\/addiction."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-5562-1_2","article-title":"Definition of substance and non-substance addiction","volume":"1010","author":"Zou Z","year":"2017","unstructured":"Zou Z, Wang H, d'Oleire Uquillas F, Wang X, Ding J, Chen H. Definition of substance and non-substance addiction. Adv Exp Med Biol. 2017, 1010:21-41. 10.1007\/978-981-10-5562-1_2","journal-title":"Adv Exp Med Biol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.04.016","article-title":"The link between schizophrenia and substance use disorder: a unifying hypothesis","volume":"194","author":"Khokhar JY","year":"2018","unstructured":"Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophr Res. 2018, 194:78-85. 10.1016\/j.schres.2017.04.016","journal-title":"Schizophr Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2020.1825892","article-title":"Impact of substance use disorder on quality of inpatient mental health services for people with anxiety and depression","volume":"17","author":"Williams R","year":"2021","unstructured":"Williams R, Farquharson L, Rhodes E, et al.. Impact of substance use disorder on quality of inpatient mental health services for people with anxiety and depression. J Dual Diagn. 2021, 17:80-93. 10.1080\/15504263.2020.1825892","journal-title":"J Dual Diagn"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13989","article-title":"The neurobiology of addiction","volume":"1451","author":"Uhl GR","year":"2019","unstructured":"Uhl GR, Koob GF, Cable J. The neurobiology of addiction. Ann N Y Acad Sci. 2019, 1451:5-28. 10.1111\/nyas.13989","journal-title":"Ann N Y Acad Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108933","article-title":"The relationship of frequency of cocaine use to substance and psychiatric disorders in the U.S. general population","volume":"227","author":"Aharonovich E","year":"2021","unstructured":"Aharonovich E, Scodes J, Wall MM, Hasin DS. The relationship of frequency of cocaine use to substance and psychiatric disorders in the U.S. general population. Drug Alcohol Depend. 2021, 227:108933. 10.1016\/j.drugalcdep.2021.108933","journal-title":"Drug Alcohol Depend"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: evidence and potential mechanisms","volume":"142","author":"Ivan Ezquerra-Romano I","year":"2018","unstructured":"Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJ. Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology. 2018, 142:72-82. 10.1016\/j.neuropharm.2018.01.017","journal-title":"Neuropharmacology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow ND","year":"2019","unstructured":"Volkow ND, Michaelides M, Baler R. The neuroscience of drug reward and addiction. Physiol Rev. 2019, 99:2115-40. 10.1152\/physrev.00014.2018","journal-title":"Physiol Rev"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pbr.2015.07.016","article-title":"PET imaging for addiction medicine: from neural mechanisms to clinical considerations","volume":"224","author":"Wiers CE","year":"2016","unstructured":"Wiers CE, Cabrera E, Skarda E, Volkow ND, Wang GJ. PET imaging for addiction medicine: from neural mechanisms to clinical considerations. Prog Brain Res. 2016, 224:175-201. 10.1016\/bs.pbr.2015.07.016","journal-title":"Prog Brain Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176413","article-title":"Alcohol addiction, gut microbiota, and alcoholism treatment: a review","volume":"21","author":"Wang SC","year":"2020","unstructured":"Wang SC, Chen YC, Chen SJ, Lee CH, Cheng CM. Alcohol addiction, gut microbiota, and alcoholism treatment: a review. Int J Mol Sci. 2020, 21:6413. 10.3390\/ijms21176413","journal-title":"Int J Mol Sci"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review","volume":"320","author":"Kranzler HR","year":"2018","unstructured":"Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018, 320:815-24. 10.1001\/jama.2018.11406","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1037\/ccp0000447","article-title":"A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition","volume":"87","author":"Magill M","year":"2019","unstructured":"Magill M, Ray L, Kiluk B, Hoadley A, Bernstein M, Tonigan JS, Carroll K. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition. J Consult Clin Psychol. 2019, 87:1093-105. 10.1037\/ccp0000447","journal-title":"J Consult Clin Psychol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar E","year":"2020","unstructured":"Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, Nunes EV. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020, 177:125-33. 10.1176\/appi.ajp.2019.19070684","journal-title":"Am J Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2020.08.012","article-title":"Cocaine triggers astrocyte-mediated synaptogenesis","volume":"89","author":"Wang J","year":"2021","unstructured":"Wang J, Li KL, Shukla A, et al.. Cocaine triggers astrocyte-mediated synaptogenesis. Biol Psychiatry. 2021, 89:386-97. 10.1016\/j.biopsych.2020.08.012","journal-title":"Biol Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax1532","article-title":"The treatment of cocaine use disorder","volume":"5","author":"Kampman KM","year":"2019","unstructured":"Kampman KM. The treatment of cocaine use disorder. Sci Adv. 2019, 5:eaax1532. 10.1126\/sciadv.aax1532","journal-title":"Sci Adv"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial","volume":"176","author":"Dakwar E","year":"2019","unstructured":"Dakwar E, Nunes EV, Hart CL, et al.. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry. 2019, 176:923-30. 10.1176\/appi.ajp.2019.18101123","journal-title":"Am J Psychiatry"},{"key":"ref43","unstructured":"Trauma-Informed care in behavioral health services. (2013). Accessed. March 13, 2022: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK207191\/box\/part1_ch3.box16\/."},{"key":"ref44","unstructured":"U.S. Department of Veterans Affairs. effects of the Coronavirus (COVID-19) pandemic on PTSD. (2020). Accessed: March 13, 2022: https:\/\/www.ptsd.va.gov\/covid\/COVID_effects_ptsd.asp."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"CDC. Symptoms of depression, anxiety, post-traumatic stress disorder, and suicidal ideation among state, tribal, local, and territorial public health workers during the COVID-19 pandemic - United States, March-April 2021. (2021). Accessed: March 13, 2022: https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7048a6.htm?s_cid=mm7048a6_w.","DOI":"10.15585\/mmwr.mm7048a5"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212305","article-title":"Ketamine as treatment for post-traumatic stress disorder: a review","volume":"8","author":"Liriano F","year":"2019","unstructured":"Liriano F, Hatten C, Schwartz TL. Ketamine as treatment for post-traumatic stress disorder: a review. Drugs Context. 2019, 8:212305. 10.7573\/dic.212305","journal-title":"Drugs Context"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14079","article-title":"A retrospective study of ketamine administration and the development of acute or post-traumatic stress disorder in 274 war-wounded soldiers","volume":"72","author":"Mion G","year":"2017","unstructured":"Mion G, Le Masson J, Granier C, Hoffmann C. A retrospective study of ketamine administration and the development of acute or post-traumatic stress disorder in 274 war-wounded soldiers. Anaesthesia. 2017, 72:1476-83. 10.1111\/anae.14079","journal-title":"Anaesthesia"},{"key":"ref48","unstructured":"Canadian Agency for Drugs and Technologies in Health. Intravenous ketamine for adults with treatment-resistant depression or post-traumatic stress disorder: a review of clinical effectiveness, cost-effectiveness and guidelines . (2019). Accessed: March 13, 2022: https:\/\/pubmed.ncbi.nlm.nih.gov\/31873996\/."},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2020.1769118","article-title":"The use of ketamine to cope with depression and post-traumatic stress disorder: a qualitative analysis of the discourses posted on a popular online forum","volume":"46","author":"Chaves TV","year":"2020","unstructured":"Chaves TV, Wilffert B, Sanchez ZM. The use of ketamine to cope with depression and post-traumatic stress disorder: a qualitative analysis of the discourses posted on a popular online forum. Am J Drug Alcohol Abuse. 2020, 46:613-24. 10.1080\/00952990.2020.1769118","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11634","article-title":"Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression","volume":"79","author":"Albott CS","year":"2018","unstructured":"Albott CS, Lim KO, Forbes MK, et al.. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry. 2018, 79:17-11634. 10.4088\/JCP.17m11634","journal-title":"J Clin Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder","volume":"178","author":"Feder A","year":"2021","unstructured":"Feder A, Costi S, Rutter SB, et al.. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021, 178:193-202. 10.1176\/appi.ajp.2020.20050596","journal-title":"Am J Psychiatry"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4786-3","article-title":"Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study","volume":"235","author":"Hartberg J","year":"2018","unstructured":"Hartberg J, Garrett-Walcott S, De Gioannis A. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. Psychopharmacology (Berl). 2018, 235:393-8. 10.1007\/s00213-017-4786-3","journal-title":"Psychopharmacology (Berl)"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01327-5","article-title":"Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder","volume":"11","author":"Davis MT","year":"2021","unstructured":"Davis MT, DellaGiogia N, Maruff P, Pietrzak RH, Esterlis I. Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder. Transl Psychiatry. 2021, 11:205. 10.1038\/s41398-021-01327-5","journal-title":"Transl Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/89385-the-therapeutic-effects-of-ketamine-in-mental-health-disorders-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:33Z","timestamp":1707507393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/89385-the-therapeutic-effects-of-ketamine-in-mental-health-disorders-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.23647","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,30]]}}}